UK monoclonal antibodies market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising demand for novel monoclonal antibodies and a significant rise in the incidences of cancer and auto-immune diseases are some pivotal factors encouraging market growth. As per the World Health Organization (WHO), the number of new cancer incidences reported in the country was 446,942 in 2018. This contributes to increasing demand for monoclonal antibodies that served as one of the potential options of targeted and immunotherapy to find and attack cancer cells. These antibodies are designed to act in different ways, including blocking cell growth and immune system inhibitors, delivering chemotherapy and radiation treatment, preventing the growth of blood vessels, flagging cancer cells, directly attacking cancer cells, and more.

UK monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Humanized monoclonal antibodies are being significantly preferred as it is an established technique to reduce the immunogenicity of monoclonal antibodies from xenogeneic sources (usually rodent). Generally, humanized monoclonal antibodies produce lower levels of anti-drug-antibodies (ADAs) than chimeric monoclonal antibodies. In addition, it is used to improve the activation of the human immune system. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. 

Some key players in the market include AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V. Product launches and partnerships and collaborations are some potential strategic initiatives adopted by the market players, to increase competitiveness in the market. For instance, in May 2020, AstraZeneca declared that it will partner with ArcherDX, a genomic analysis company engaged in precision oncology. Under the partnership, AstraZeneca will use ArcherDX personalized cancer monitoring which aims to detect minimal residual disease in patients having early-stage non-small cell lung cancer (NSCLC). This personalized assay will be utilized in the Phase III MERMAID-1 trial of AstraZeneca to assess the outcome of adjuvant treatment with Imfinzi (durvalumab). It is a human monoclonal antibody along with chemotherapy versus chemotherapy alone on disease-free survival. 

Research Methodology

The market study of the UK monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Monoclonal Antibodies Market Research and Analysis by Source
2. UK Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the UK monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK monoclonal antibodies market.
• Insights about market determinants which are stimulating the UK monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.